Tyme Inc. (TYME) Misses Q4 EPS by 12c

Tyme Inc. (NASDAQ: TYME) reported Q4 EPS of ($0.19), $0.12 worse than the analyst estimate of ($0.07).

• TYME-88-Panc pivotal trial enrolling patients using oral SM-88 as a potential treatment for third-line pancreatic cancer
• PanCAN enrolling patients in its Precision PromiseSM adaptive randomized Phase II/III registration-intent trial evaluating oral SM-88 as second-line monotherapy for pancreatic cancer
• TYME & Joseph Ahmed Foundation’s HopES sarcoma study enrolling patients for the investigator-initiated Phase II trial studying oral SM-88 as maintenance monotherapy in previously treated metastatic Ewing’s sarcoma and salvage monotherapy in clinically advanced sarcomas
• TYME to present updated findings from preclinical data on cancer metabolism-based compounds: SM-88 and TYME-18
• Strategic collaboration with Eagle Pharmaceuticals entitled TYME to receive up to a total of $40 million, which included $20 million upfront and $20 million in potential milestone payments
• Additional capital resources better position TYME to carry out its clinical trials in pancreatic cancer and sarcomas, advance plans for clinical trials in metastatic breast, prostate and/or hematological cancers, as well as continue developing pre-clinical and mechanism data studies
• Fourth Quarter and Fiscal Year 2020 conference call today, May 20th, at 5 p.m. Eastern Time

“Fiscal Year 2020 was our most productive year to date in which we made significant progress on our key initiatives across all functions of our business. The positive results across multiple studies achieved in fiscal 2020 positioned TYME to initiate our first pivotal trial in pancreatic cancer, partner with PanCAN for the innovative Precision Promise trial, start the phase II trial for high-risk sarcomas, and produce encouraging top line data from Part 1 of the TYME-88-Panc study. We witnessed promising final data in the Phase II biomarker recurrent prostate trial and strengthened our capital structure,” said Steve Hoffman, Chairman and Chief Executive Officer of TYME. “We believe these combined achievements should enhance the value of TYME and serve as our engine of growth for the next several years. Importantly, each milestone that we accomplished strengthens our conviction in achieving our fiscal 2021 corporate goals and objectives toward improving the lives of patients with advanced cancers.”

For earnings history and earnings-related data on Tyme Inc. (TYME) click here.

You May Also Be Interested In

• Xos posts higher gross margins but lower revenue in Q2 2026
• KinderCare Learning Companies, Inc. (KLC) Misses Q2 EPS by 2c; Offers Guidance
• Nektar Therapeutics (NKTR) Tops Q2 EPS by 77c